

*This is a free translation of the Adocia's table of financial resolutions issued in the French language, for informational purposes only.*

## DESCRIPTIVE TABLE ON THE FINANCIAL RESOLUTIONS TO BE SUBMITTED TO THE COMBINED SHAREHOLDERS' MEETING OF JUNE 3, 2026 (\*)

The table below summarizes the key elements of each of the financial resolutions to be submitted to the combined Shareholders' Meeting of Adocia (the « **Company** ») to be held on June 3, 2026.

Resolution N°	Subject matter of the resolution	Description
15	Authorization to be given to the Board to reduce stated capital by cancelling shares pursuant to the authorization to purchase its own shares.	<ul style="list-style-type: none"> <li>- Limitation of 10% of registered capital per 24 months.</li> <li>- Validity period: 18 months.</li> <li>- Delegation cannot be used during a public offer.</li> <li>- Renewal of the 16<sup>th</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>
16	Delegation of authority to the Board of Directors to increase the Company's capital, up to a maximum of 30% of the capital, by issuing ordinary shares and/or any other securities without shareholders' pre-emptive subscription rights, to the benefit of persons designated by name - delegation to the Board of Directors of the power to designate such persons.	<ul style="list-style-type: none"> <li>- Total nominal amount of capital increases that may be carried out: € 590,000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued: € 50,000,000.</li> <li>- Subject to the overall cap set out in the 22<sup>nd</sup> resolution.</li> <li>- An offering price set by the Board that is at least equal to the closing price on the last trading day preceding the Board's decision, less a discount of up to 10%.</li> <li>- Delegation cannot be used during a public offer.</li> <li>- Duration of delegation: 18 months.</li> <li>- Up to a maximum of 30% of the capital per 12-month period.</li> <li>- Renewal of the 20<sup>th</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>

\* See the text of resolutions for more details.

17	Delegation of authority to be granted to the Board to increase capital immediately or in the future by issuing common shares and/or equity securities, without a preemptive subscription right for shareholders, for the benefit of a category of persons that satisfy specified characteristics (active investors in the sector health or biotechnologies).	<ul style="list-style-type: none"> <li>- Total nominal amount of the capital increases that may be decided: € 590,000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued: € 50,000,000.</li> <li>- Within the limit of the overall cap provided for in the 22<sup>nd</sup> resolution.</li> <li>- Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%).</li> <li>- Delegation cannot be used during a public offer.</li> <li>- Validity period: 18 months.</li> <li>- Renewal of the 21<sup>st</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>
18	Delegation of authority to be granted to the Board to increase capital immediately or in the future by issuing common shares and/or equity securities, without a preemptive subscription right for shareholders, for the benefit of a category of persons that satisfy specified characteristics (strategic or financial partners).	<ul style="list-style-type: none"> <li>- Total nominal amount of the capital increases that may be decided: € 590,000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued: € 50,000,000.</li> <li>- Within the limit of the overall cap provided for in the 22<sup>nd</sup> resolution.</li> <li>- Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%).</li> <li>- Delegation cannot be used during a public offer.</li> <li>- Validity period: 18 months.</li> <li>- Renewal of the 22<sup>nd</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>
19	Delegation of authority granted to the Board of Directors to increase capital by issuing common shares with or without a preemptive subscription right for shareholders as decided in the above-mentioned resolutions.	<ul style="list-style-type: none"> <li>- Possibility to increase by 15% the number of securities to be issued in the event of a capital increase with or without a preemptive subscription right for shareholders, within the limit of 15% of the initial increase under the above resolutions.</li> <li>- At the same price as the original issue and within the limit of 15% of the initial issue.</li> <li>- Within the limit of the overall cap provided for in the 22<sup>nd</sup> resolution.</li> <li>- Validity period: 26 months.</li> <li>- Renewal of the 23<sup>rd</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>

20	Delegation of authority granted to the Board of Directors to issue common shares and/or equity securities as part of a public offer comprising an exchange component initiated by the Company.	<ul style="list-style-type: none"> <li>- Total nominal amount of the capital increases that may be decided: € 200,000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued: € 50,000,000.</li> <li>- Within the limit of the overall cap provided for in the 22<sup>nd</sup> resolution.</li> <li>- Validity period: 26 months.</li> <li>- Renewal of the 24<sup>th</sup> resolution of the shareholders' meeting of June 13, 2024.</li> </ul>
21	Delegation of authority granted to the Board of Directors to decide to issue common shares and/or equity securities giving immediate or deferred access by all means, to shares or other equity securities of the Company, for an amount not exceeding 10% of stated capital, to remunerate shares or marketable securities giving rights to the share capital of third-party companies, except in the event of a public exchange offer.	<ul style="list-style-type: none"> <li>- Total nominal amount of the capital increases that may be decided: € 200,000.</li> <li>- Total nominal amount of capital increases that may be issued limited to 10% of the capital.</li> <li>- Within the limit of the overall cap provided for in the 22<sup>nd</sup> resolution.</li> <li>- Validity period: 26 months.</li> <li>- Renewal of the 25<sup>th</sup> resolution of the shareholders' meeting of June 13, 2024.</li> </ul>
22	Overall limits on the issues completed pursuant to the sixteenth resolution through the twenty-first resolution.	<ul style="list-style-type: none"> <li>- Total nominal amount of capital increases that may be decided pursuant to the 16<sup>th</sup> resolution through the 21<sup>st</sup> resolution: € 1,020,000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued: € 50,000,000.</li> <li>- Renewal of the 24<sup>th</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>
23	Delegation of authority to the Board of Directors to increase the Company's capital by issuing ordinary shares and/or other securities, without pre-emptive subscription rights for existing shareholders, for the benefit of a category of persons meeting specified criteria within the scope of an equity or bond financing agreement.	<ul style="list-style-type: none"> <li>- Total nominal amount of the capital increases that may be decided: € 390,000.</li> <li>- Maximum nominal amount of debt securities giving access to share capital that can be issued: € 50,000,000.</li> <li>- Issue price fixed by the Board and at least equal to the weighted average of the last three trading days, minus a legal maximum discount (i.e. 20%).</li> <li>- Limit set separately from the cap referred to in the 22<sup>nd</sup> resolution.</li> <li>- Delegation cannot be used during a public offer.</li> <li>- Validity period: 18 months.</li> </ul>

		<ul style="list-style-type: none"> <li>- Renewal of the 25<sup>th</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>
24	<p>Authorization for the Board of Directors to grant existing shares or shares to be issued without consideration, in accordance with the provisions of Articles L. 225-197-1 et seq. of the French Commercial Code, with shareholders waiving their pre-emptive subscription rights.</p>	<ul style="list-style-type: none"> <li>- Maximum number of shares that may be issued: 580,000.</li> <li>- Vesting period of at least 1 year and cumulative vesting and holding period of at least 2 years.</li> <li>- Within the overall cap set in the 26<sup>th</sup> resolution.</li> <li>- Term of delegation: 38 months.</li> <li>- Renewal of the 27<sup>th</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>
25	<p>Delegation of authority to the Board of Directors to issue and grant stock warrants without pre-emptive subscription rights to (i) members and non-voting members of the Company's Board of Directors in office at the date of grant of the warrants, (ii) persons bound to the Company or one of its subsidiaries by a service or consultancy contract, or (iii) members of any committee that the Board of Directors has set up or may set up in the future.</p>	<ul style="list-style-type: none"> <li>- The issue price of a warrant will be at least equal to 15% of the volume-weighted average price of the last 5 trading sessions.</li> <li>- Maximum number of shares that can be issued upon exercise of BSA: 325,000.</li> <li>- Subscription price of the share to which the BSA gives right must at least be equal to the highest value between (i) sale price of a share the day before the allocation, and (ii) the weighted average of the last 20 trading sessions.</li> <li>- Validity of the BSA: 10 years.</li> <li>- Subject to the overall cap set out in the 26<sup>th</sup> resolution.</li> <li>- Validity period: 18 months.</li> <li>- Renewal of the 28<sup>th</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>
26	<p>Overall limits on the amount of issues carried out pursuant to the twenty-fourth and twenty-fifth resolutions.</p>	<ul style="list-style-type: none"> <li>- Total number of shares that may be issued under the 24<sup>th</sup> and 25<sup>th</sup> resolutions may not exceed 980,000 shares.</li> <li>- Renewal of the 29<sup>th</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>

27	Delegation to be granted to the Board to increase stated capital by issuing shares without a preemptive subscription right for shareholders in favor of the employees who participate in a corporate savings plan.	<ul style="list-style-type: none"> <li>- Capital increase reserved for employees who are members of a corporate savings plan of the Company.</li> <li>- Total nominal amount of the capital increases that may be decided: € 20,000.</li> <li>- The issue price of shares giving access to capital will be determined by the board of directors and may not be higher than the average of the prices quoted at the 20 trading sessions preceding the day of the decision of the board of directors fixing the date subscription opening period or more than 20% below this average or 30% when the unavailability period provided for by the plan is greater than or equal to 10 years.</li> <li>- Validity period: 18 months.</li> <li>- Renewal of the 31<sup>st</sup> resolution of the shareholders' meeting of June 11, 2025.</li> </ul>
28	Modification of the article 19 of the bylaws.	<ul style="list-style-type: none"> <li>- Removal of the requirement for prior consent from registered shareholders for electronic notice of meetings; this provision applies to meetings convened on or after July 1, 2026.</li> <li>- The record date for shareholders has been extended from 2 to 5 business days prior to the date of the annual meeting.</li> </ul>